Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
  • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
  • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
  • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• the present invention relates to a composition of pheromones useful to treat or prevent a behavioral stress problem of a non-human mammal. It also relates to a device comprising said composition and to a method for preventing and/or treating stress-related behaviors in a non-human mammal, by using said composition or device.
• Pheromone therapy “pheromonatherapy”, or “pheromonotherapy” is a way to manage behavior problems in non-human mammals by using chemicals that have pheromonal properties. It is an innovative treatment of stress related problems for non-human mammals, such as non-companion animal species, including pigs and poultry, or domestic animal species, such as cats and dogs. The pheromonatherapy has been studied most extensively in dogs and cats.
• Pheromones are chemical substances used for communication between individuals of the same species. Some chemicals that provide interspecies communication are called allelochemicals. Some compounds are known to be a pheromone in one species, but have been observed to have behavioral effects in other species. Pheromones will be used herein in a large sense, i.e. any naturally or non-naturally occurring compound that have a behavioral impact on non-human mammals. The precise mechanism of action of most pheromones is still unknown but they induce some modifications in both the limbic system and the hypothalamus.
• Pheromonotherapy is a great way of managing non-human mammals welfare and more particularly some common stress-related behavioral disorders in domestic mammals, such as dogs and cats, without the need for drugs and their associated side-effects.
• Pheromonotherapy is successfully used to prevent and/or treat at least one medical or behavioral stress problem of a non-human mammal for pets and especially for cats and dogs.
• Feliway® Ceva Santé Animale
• the product mimics the feline's facial pheromones and can be used to calm the pet in stressful situations.
• Feliway® decreases the cat's arousal and stops urine marking and vertical scratching, and other stress-related behaviours. The user always needs to wait for about 15 minutes before letting the cat near any Feliway® sprayed areas, in particular as to let the volatile carrier solvent evaporate.
• Feliway® devices have been developed and commercialized by Ceva Santé Animale. These plug-in offer a no-hassle way for pet owners to calm their cats. The pet owner has just to attach the Feliway® source to the plug-in diffuser, plug it into an electric socket in the room most used by the cat, and continue use for four weeks with a liquid plug in diffuser to ensure no relapse in marking behavior.
• dog appeasing pheromone (DAP® or Adaptil®; Ceva Sante Animale) is a synthetic analog of natural dog-appeasing pheromone that has been promoted as an adjunct treatment to improve conditions such as separation-related behavior problems, loud noise phobias, stress and anxiety.
• Dog-appeasing pheromone has been reported to reduce separation-induced anxiety, fear in puppies in a new environment and anxiety and stress during transportation. It can also decrease the stress of dogs in public shelter, the training-derived stress of working dogs (police dogs, guide dogs) and the anxiety of puppies in learning and socialization processes.
• Adaptil® might be a potential treatment for dogs that are fearful of fireworks. Use of Adaptil® in veterinary clinics was significantly associated with greater relaxation in dogs, but did not have an effect on aggression.
• Adaptil® is available in two main forms: spray and plug in diffuser.
• Adaptil® spray must be sprayed 15 minutes before the dog is introduced into the environment (car, carrier, kennel, etc.), in particular to get the volatile carrier solvent evaporated. Effects should last approximately 4-5 hours and repeated applications can be necessary if the dog owner notice a reduced effect. It is recommended not to spray Adaptil® directly on animals nor near an animal's face. Adaptil® diffuser can be plugged into an electric socket in a room, frequently used by the dog, and continually used for four weeks with a liquid plug in diffuser to comfort both puppies and adult dogs.
• Feliway MultiCat® a feline appeasing pheromone to reduce social tension and conflict between cats living in the same home.
• Feliway MultiCat® pheromone is a synthetic copy of the pheromone produced by a mother cat during lactation. This appeasing pheromone reassures their kittens and helps them bond with the mother.
• Social tension between cats may impair the cat's day to day welfare.
• Conflict between cats can begin when a new cat is introduced into the home or previously amicable relationships may change when an event happens that causes one or more cats to become distressed. The cats may have an aggressive encounter and then fail to mend their relationship. Signs of social tension and conflict between familiar cats may be obvious or quite subtle.
• Overt aggression may include hissing, growling, screaming, hissing, swatting, or chasing.
• Passive or avoidant behaviors are common too including hiding, fleeing or blocking.
• Meridian Animal Health Company launched Nutricalm 24/7 Pheromone Collars for cats and dogs to provide round-the-clock pheromone release. The pheromones in the collars mimic those puppies and kittens are exposed to while nursing and create feelings of security and well-being, even in adulthood.
• Perrigo company launched the Sentry® Good BehaviorTM pheromone products to reduce and eliminate problems like inappropriate marking, scratching, digging and even pet/owner separation.
• Virbac company launched in 2015 a product branded Zenifel® comprising a F3 feline's facial pheromone analogue which can be used to calm the cat in stressful situations.
• This product contains 10% of pheromone fraction of the total weight for the spray composition and 2% for the plug-in device.
• All pheromone products currently available to treat or prevent behavior problems in non-human mammals such as dogs and cats are characterized by a pheromonal fraction around 2 to 10% of the total weight of said composition.
• This present invention relates to a composition
• a composition comprising pheromones in an amount of less than about 1% by weight with respect to the total weight of said composition.
• composition according to the invention is suitable for a use to treat at least one behavioral stress problem of a non-human mammal, in particular by administration of the composition to said mammal.
• Another object of the present invention is a device comprising a composition of the invention, the device being more specifically suitable for a use to treat at least one behavioral stress problem of a non-human mammal.
• composition relates to a device comprising said composition and to a method for the treatment of a stress-related behavior in a non-human mammal, by using said composition or device.
• pheromone » refers to any compound that mimics certain naturally occurring pheromones that have a behavioral impact, such as a calming or appeasing effect, on mammals. It includes any naturally occurring pheromones, said naturally occurring pheromones are one or more secreted compounds by an organism of a specific species which entails a foreseeable reaction (such as for example a calming effect) to another mammal of the same species or another species. As specified earlier, pheromones will be used herein in a large sense, i.e. any naturally or non-naturally occurring compound that have a behavioral impact on non-human mammals. The precise mechanism of action of most pheromones is still unknown but they induce some modifications in both the limbic system and the hypothalamus.
• the term “about” or “approximately” or “around” will be understood by a person of ordinary skill in the art and will vary to some extent on the context in which it is used. If there are uses of the term which are not clear to persons of ordinary skill in the art given the context in which it is used, “about” will mean up to plus or minus 15% of the particular term.
• Non-human mammals is intended to mean all animals with the exception of human.
• the non-human animals include domestic, farm, and zoo animals, including cats, dogs, horses, cattle, tigers, lions, bears, elephants, pigs, boars, etc.
• cats or dogs when cited by way of example, it can be generalized to any other domestic, farm, and zoo animals. More specifically, it refers to cats and dogs, and more specifically cats.
• the term “comprise(s)” or “comprising” is “open-ended” and can be generally interpreted such that all of the specifically mentioned features and any optional, additional and unspecified features are included. According to specific embodiments, it can also be interpreted as the phrase “consisting essentially of” where the specified features and any optional, additional and unspecified features that do not materially affect the basic and novel characteristic(s) of the claimed invention are included or the phrase “consisting of” where only the specified features are included, unless otherwise stated.
• object means any physical thing that can be seen and touched.
• objects includes any object that a feline may scratch including, but not limited to, rugs, furniture, carpets, drapes, upholstered corners of couches and chairs, wall papered surfaces, cardboard storage boxes, wood trim on doors and walls. These are only a very few examples defined to encompass the term objects that is used herein.
• feline including cats may use or uses at least one specific object for scratching (i.e. scratching object), such as cat posts, cat platforms, cat carpets, cat boards, cat toys, cat trees, and the like.
• fatty acid » refers to monocarboxylic and dicarboxylic acids with hydrocarbon chains, saturated or unsaturated, linear or branched, liable to have a behavioral impact on stress of non-human mammals.
• “Derivatives of fatty acids” means all active derivatives of fatty acids. Preferably, the derivatives are in ester (such as methyl ester) or salt forms.
• composition of the invention comprises pheromones in an amount of less or equals to about 1% by weight with respect to the total weight of said composition.
• pheromones correspond to at least one fatty acid or derivative thereof, more specifically salt or ester thereof, such as methyl ester.
• the present invention relates to a composition
• a composition comprising one or more pheromones, preferably one or more fatty acids or derivatives thereof, as active ingredients, in an amount of less or equal to about 1% by weight with respect to the total weight of said composition, preferably less or equal to about 0.9, 0.8, 0.7, 0.6, or 0.5% by weight with respect to the total weight of said composition.
• the composition comprises one or more pheromones, preferably one or more fatty acids or derivatives thereof, as active ingredients, in an amount more than or equal to about 0.3% or 0.4% by weight with respect to the total weight of said composition.
• the fatty acids preferably have from 3 to 22 carbon atoms. They can be selected for instance from propanoic acid (propionic), butanoic acid (butyric), pentanoic acid (valeric), hexanoic acid (caproic), heptanoic acid (enanthic), octanoic acid (caprylic), nonanoic acid, decanoic acid (capric), undecanoic acid (undecylic), dodecanoic acid (lauric), tridecanoic acid (tridecylic), pentadecanoic acid, heptadecanoic acid (margaric), octadecanoic acid (stearic), eicosanoic acid (arachidic), arachidonic acid, heneicosanoic acid (heneicosylic), tricosanoic (tricosylic), tetracosanoic acid (lignoceric), pentacosanoic acid (
• they are chosen among oleic acid, palmitic acid, azelaic acid, pimelic acid, capric acid, myristic acid, palmitoleic acid, linoleic acid, linolenic acid, stearic acid, valeric acid, arachidonic acid, lauric acid, n-butyric acid, isobutyric acid, [alpha]-methylbutyric acid, pivalic acid, linoleic acid, eicosapentanoic acid, pentadecanonic acid, tridecanoic acid, docosahexanoic acid, salt or ester thereof, and a mixture thereof.
• compositions may comprise at least one fatty acid such as oleic acid, linoleic acid, palmitic acid, valeric acid, a derivative thereof, or a mixture thereof.
• fatty acid such as oleic acid, linoleic acid, palmitic acid, valeric acid, a derivative thereof, or a mixture thereof.
• fatty acid mixtures or their derivatives, ester or methyl ester derivatives, such as:
• a mixture of oleic and palmitic acid a mixture of oleic and n-butyric acid; a mixture of valeric and linoleic acid; a mixture of oleic acid, palmitic acid and linoleic acid; a mixture of oleic acid, palmitic acid, linoleic acid and palmitoleic acid; a mixture of capric acid, lauric acid, myristic acid, palmitoleic acid, palmitic acid, linoleic acid and oleic acid; a mixture of oleic acid, palmitic acid, linoleic acid, myristic acid; a mixture of oleic acid, palmitic acid, linoleic acid, lauric acid and myristic acid a mixture of oleic acid, palmitic acid, linoleic acid, myristic acid and pentadecanonic acid; a mixture of oleic acid, palmitic acid,
• the composition comprises valeric acid and linoleic acid (or derivative thereof), as pheromones, in an amount of less than or equal to about 1% by weight with respect to the total weight of said composition, preferably less or equal to about 0.9, 0.8, 0.7, 0.6, or 0.5% by weight with respect to the total weight of said composition.
• the amount of valeric acid and linoleic acid (or derivative thereof), as pheromones is more than or equal to about 0.3% or 0.4% by weight with respect to the total weight of said composition.
• the mixture may comprise the above-mentioned fatty acids in appropriate proportions which are well known to any skilled person.
• the mixtures can contain (% are expressed by weight with respect to the total weight of the cited compounds):
• the pheromones used herein are compounds to treat or prevent a behavioral stress problem of a non-human mammal, more particularly either cats or dogs, preferably cats.
• the fatty acid mixture comprises a mixture of appeasing fatty acids for cats.
• this mixture comprises at least a therapeutically effective amount of active fatty acids, derivatives thereof, salt or ester thereof and preferably chosen among lauric acid, myristic acid, stearic acid, linoleic acid, oleic acid, valeric acid, azelaic acid, pimelic acid, palmitic acid, and a mixture thereof.
• the mixture of fatty acids preferably comprises linoleic acid and valeric acid.
• the mixture comprises a mixture of fatty acids that are appeasing for dogs.
• this mixture comprises a therapeutically effective amount of fatty acids, their derivatives, salt or ester thereof.
• fatty acids their derivatives, salt or ester thereof.
• These are preferably chosen among lauric acid, myristic acid, pentadecanoic acid, palmitic acid, stearic acid, oleic acid and linoleic acid.
• a mixture of ester fatty acids for dogs comprises about 35% of methyl oleate, about 2% of methyl laurate, about 13% methyl stearate, about 21% methyl linoleate, about 5% methyl myristate, about 4% methyl pentadecanoate, and about 20% methyl palmitate.
• the composition further comprises lactic acid or an ester thereof, such as methyl or ethyl lactacte.
• the composition further comprises ethyl lactate.
• the composition comprises valeric acid, linoleic acid and ethyl lactate. Ethyl lactate is preferred since it seems less degraded during storage than its acid form.
• the mixture of valeric acid, linoleic acid and ethyl lactate is in appropriate proportions which are preferably about 75-85% of linoleic acid, 5-15% of valeric acid, and 10-20% of ethyl lactate (% are expressed by weight with respect to the total weight of the cited compounds).
• composition of the invention can be formulated in any form such as a powder, spray, liquid, gel or aerosol, having components known to those skilled in the art.
• the composition further comprises an acceptable carrier.
• Said acceptable carrier includes compounds well known to one of skill in the art and comprises excipients and auxiliaries which facilitate processing of the pheromones into preparations which can be used for non-human mammals. Further details on techniques for formulation and administration may be found in the latest edition of “Development and Formulation of Veterinary Dosage Forms” edited by Gregory E. Hardee and J. Desmond Baggot (1998)
• the pheromone based composition is in a solution form (from oily to liquid phases).
• the composition of the present invention preferably comprises at least one solvent.
• the solvent includes glycols, such as propylene glycol, diethylene glycol, glycol ethers (e.g., mono- or di-alkyl ethers of ethylene glycol), such as ethylene glycol monomethyl ether, ethylene glycol monoethyl ether, ethylene glycol monopropyl ether, ethylene glycol monoisopropyl ether, ethylene glycol monobutyl ether, ethylene glycol monophenyl ether, ethylene glycol monobenzyl ether, diethylene glycol monomethyl ether, diethylene glycol monoethyl ether, diethylene glycol mono-n-butyl ether, ethylene glycol dimethyl ether, ethylene glycol diethyl ether, ethylene glycol dibutyl ether, and the like.
• the solvents may also be selected from alcohol (such as ethyl alcohol, propyl alcohol, isopropanol, 2-propanol,), ether, chloroform, benzene, acetone,
• the active ingredients may be combined with any solid or liquid additives corresponding to the usual techniques of formulation development.
• the composition may also comprise at least one volatile organic compound, including, but not limited to, ketones, such as acetone, alcohols, sterols and the like.
• the composition may also comprise coloring agents.
• the composition may also comprise at least one antioxidant.
• antioxidants include without limitation, sulfate compounds, L-cysteine, thiodipropionic acid, thiolactic acid, monothioglycerol, propyl galate sodium metabisulfite, sodium formaldehyde, sulfoxylate acetate, butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT), vitamin E, ascorbic acid (vitamin C), vitamin B12, or a combination of these agents.
• BHA butylated hydroxyanisole
• BHT butylated hydroxytoluene
• vitamin E ascorbic acid
• vitamin B12 or a combination of these agents.
• the antioxidants, such as BHT may be present in the composition described herein in an amount of 0.001% to 0.1% by weight with respect to the total weight of said composition.
• the antioxidants, such as BHT can also be present in the amount of 0.005% to 0.015% by weight with respect to the total weight of said composition, preferably
• Cat attractants can also be optionally added to the composition. These include catnip (Nepeta Cataria), essential oil of catnip, tatarian honeysuckle ( Lonicera tartarica ), Valerian ( Valerriana officicinalis ), silver vine/matatabi ( Actinidia polygama ), cat thyme ( Teucrium maxum ), Buckbean ( Menyanthes trifoliate ), actinidine, actinidiolide, boschnialactone, boschniakine, dihydroactinidiolide, dihydronepetalactone, epinepetalactone, iridomyrmecin, isodihydronepetalactone, missugashiwalactone, neonepetalactone, onikulactone and mixtures thereof.
• catnip Nepeta Cataria
• essential oil of catnip tatarian honeysuckle
• Valerian Valerriana officicinalis
• silver vine/matatabi Actinidia
• the cat attractants may be present in the composition described herein in an amount of 0.02% to 0.20%, preferably 0.05% to 0.15%, by weight with respect to the total weight of said composition. They can also be present in the amount of 0.01% to 0.10% by weight with respect to the total weight of said composition, preferably 0.1%.
• Additional components may optionally be included such as, but not limited to, plasticizers, fragrances, coloring agents, preservatives, light stabilizers, and the like.
• An object of the invention is a use of the composition as defined herein to prevent and/or treat of at least one behavioral stress problem of a non-human mammal, in particular by administration of the pheromones based composition to said non-human mammal.
• the administration of the pheromones based composition to a non-human mammal can be made directly or indirectly.
• the composition of pheromones according to the invention can be administered to a non-human mammal by propelling or applying the composition onto, over or nearby the non-human animal or a part thereof.
• the method of administration of the composition according to the invention can be implemented in a place where a non-human mammal is located.
• the place can be of any kind, such as for example a confined place, for instance a car, truck, carrier, small house or kennel.
• the pheromones-based composition can also be applied to any scratching object in which the cat has or may have a tendency to scratch, such as cat posts, cat platforms, cat carpets, cat boards, cat toys, cat trees, and the like. This can help the cat not to scratch somewhere else.
• the invention relates to a method for preventing a cat from scratching on multiple objects, said method comprising placing at least one composition of the invention on a scratching object (i.e.: an object dedicated for scratching).
• a scratching object i.e.: an object dedicated for scratching
• the administration onto a non-human mammal or a part thereof or the application on an object can be carried out by propelling, spraying, applying or diffusion of the composition of pheromones depending on the forms (solution, solid%) of the composition.
• the amount of pheromones to be administered according to the invention varies and depends for instance on the nature of pheromones and the non-human mammal but it should be sufficient to prevent and/or treat behavioral stress problems of a non-human mammal.
• the effect should be obtained immediately, e.g. within less than 10 minutes, more preferably less than 5 minutes.
• the administration can be renewed, one, two or three times, if no satisfactory effect is obtained or if reduced effect is observed.
• composition of pheromones as defined above is particularly effective to prevent and/or treat at least one behavioral stress problem of a non-human mammal.
• composition of pheromones according to the present invention can prevent territorial urinary marking and/or familiarize the animals with a new environment, and/or prevent noisy outbursts, soiling, destructions, scratching, stamping in the territories or aggressiveness.
• composition of pheromones may take place over very short periods of time, such as for example during traveling periods, or, on the contrary, can be repeated whenever necessary depending on the animal behavior. It can be renewed if necessary according to stress behaviors of the non-human mammals.
• the administration or application is repeated once a day for two or more days, such as 3, 4, 5, 6, 7, or 8 days, then the frequency of administration can be diminished, such as once weekly for one, two, three or four more applications, to achieve behavioural changes (as to manage for instance cat's scratching behaviours).
• composition according to the present invention is particularly efficient on canine and feline and more especially on dogs and cats.
• Behavior stress origins for dogs today could be found for example in the owners' hectic lifestyles difficult to cope with, because owners are constantly on the go whether it be moving house, going on holiday, having parties and even loud noises people make for fun like fireworks night. Accordingly, behavior stress signs increases such as for example excessive barking, agitation, trembling, shaking, shivering, drooling/salivating, cowering and hiding, licking, scratching, yawning, clinging to owners, trying to run away/attempting to escape, soiling the place, excessive pacing and panting, refusing to eat, vomiting, whining, urinating/defaecating, or any combination of said signs.
• Cats unlike dogs, are considered to be territorial animals. They have very specific behaviors centralized around their territory. Only when their environment is secure will some cats develop a relationship with other pets or humans. Stress origins for cats can be for example multi-cat households, visiting the vets, moving home, new house furniture and redecorating, cat carrier . . . The behavior stress signs in cats can be illustrated for example by scratching, urine marking, aggression, food intake disorders (over-feeding), overgrooming (bald areas) or undergrooming (matted or soiled fur), house soiling, decreased levels of activity, appearing withdrawn (reduced desire to play or interact to owners), or any combination of said signs.
• compositions, mixtures, uses and methods according to the present invention thus allow preventing and/or treating at least one behavioral stress problem of a non-human mammal. For example, repetitive urinary markings of cats occurring in case of stress of cats due to circumstances or particular changes to their immediate environment. It also allows the improvement of the conditions for the non-human mammals to familiarize themselves with their new environment, especially during travels, and/or to prevent stamping and territorial destructions, and/or reduce noisy outbursts.
• the compositions, and mixtures according to the present invention are thus intended to be used in circumstances where, for instance, a dog or a cat has shown, or is anticipated to show, signs of stress when being transported in a car.
• the beneficial effects can be measured for example by the reduction of the urinary markings and by the repeated physical contact or rubbing against new objects and people that surround them.
• the composition of pheromones according to the present invention when applied on a scratching object allows orientation or reorientation of the cats to said object, and consequently prevents a cat from scratching on multiple objects.
• the composition of pheromones according to the present invention allows the improvement of behavior of the non-human mammals in their environment and people present in that environment, with a notable reduction of stress, urinary marking and/or noisy outbursts, as well as behavior that is non aggressive and more relaxed and more affectionate, especially with their owners.
• composition of pheromones according to the invention may be administered by any means or devices suitable for administration, preferably in ambient temperature, of said composition to a non-human mammal or a part thereof or to any object that a non-human mammal has or may have the habit to touch or scratch.
• the present invention also deals with a device comprising a composition of the invention, preferably the device presents means for the release of the composition of pheromones.
• the device may also comprise means to apply, propel, diffuse or spray the said composition.
• composition of pheromones preferably presents itself under a liquid or a gel form.
• the said device may be, for example, a container, such as a bottle, with a spraying means.
• a kit comprising a device may also be envisaged, the said kit comprising a device, in particular at least one container or a number of containers, such as vials, a composition as defined in the present invention, and optionally a booklet giving instructions to use said device.
• the said device may be in ready-to-use form, i.e. prefilled, or may need to be filled before use.
• An object of the invention is a use of the composition or kit as defined herein to treat or prevent a behavioral stress problem of a non-human mammal.
• the kit comprises at least one vial comprising the composition of the invention and optionally a booklet giving instructions to use said at least one vial.
• the device or kit according to the invention is suitable for a use to prevent and/or treat of at least one behavioral stress problem of a non-human mammal, in particular by administration of the pheromones-based composition comprised therein to said non-human mammal or by application of the pheromones-based composition comprised therein on an object, as detailed above.
• Formulas of the compositions according to the invention are detailed in Table 1 below. They were prepared by mixing of the ingredients.
• Stability of Formula A was tested over a 7 month-period in a white glass flask and carried out under two controlled temperature and humidity conditions (40° C. and 75% Relative Humidity (RH) or 25° C. and 60% RH). Detection and measures of the valeric acid, ethyl lactate and linoleic acid were made by using Gas chromatography (GC).
• GC Gas chromatography
• Approximately 490 mg of linoleic acid, 53 mg of valeric acid and 78 mg of ethyl lactate accurately weighed are introduced into a 50 ml volumetric flask. This is completed to volume with ethyl acetate. The solution is stirred for at least 10 minutes. A dilution 1/20 is made and completed to volume with ethyl acetate and the solution is stirred to homogenize.
• Valeric acid ( ⁇ 5.2 min), linoleic acid ( ⁇ 13.5 min) and ethyl lactate ( ⁇ 2.7 min) are quantified and contents thereof (% w/w) are given by the ratio of the areas of the peak corresponding to valeric acid, linoleic acid or ethyl lactate in the chromatogram obtained with the sample preparation and the standard solution.
• the product is the liquid formula A as defined above.
• the formula is in a small plastic squeeze tube (5 mL) to be applied in a vertical line on a dedicated scratch post. This process is repeated once a day for 7 days then once weekly for 3 more applications. 10 tubes are furnished to the participants in a pack. 10 applications were made, one for each of 7 consecutive days and three follow-up applications to be used once every 7 days until used up (i.e. total usage period of one month).

Landscapes

• Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Epidemiology (AREA)
• Emergency Medicine (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Agricultural Chemicals And Associated Chemicals (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Applications Claiming Priority (3)

Related Parent Applications (1)

Related Child Applications (1)

Publications (1)

Family

ID=53776533

Family Applications (2)

Family Applications After (1)

Country Status (3)

Cited By (2)

Citations (2)

Family Cites Families (3)

• 2015
  • 2015-07-31 EP EP15306249.2A patent/EP3124020A1/fr not_active Withdrawn
• 2016
  • 2016-07-29 WO PCT/EP2016/068174 patent/WO2017021305A1/fr active Application Filing
  • 2016-07-29 US US15/748,671 patent/US20180200219A1/en not_active Abandoned
  • 2016-07-29 EP EP16745721.7A patent/EP3328371B1/fr active Active
• 2019
  • 2019-11-06 US US16/675,288 patent/US11331296B2/en active Active

Patent Citations (2)

Also Published As

Similar Documents

Legal Events